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Abstract
Background: Anaplastic lymphoma kinase-positive diffuse large B-cell lymphoma (ALK-DLBCL) is
a rare lymphoma with several clinicopathological differences from ALK-positive anaplastic large cell
lymphoma (ALCL). The latest WHO classification of lymphomas recognizes ALK-DLBCL as a
separate entity.
Methods: A comprehensive comparison was made between the clinical and pathological features
of the 4 cases reported and those found in an extensive literature search using MEDLINE through
December 2008.
Results: In our series, three cases were adults and one was pediatric. Two cases had primary
extranodal disease (multifocal bone and right nasal fossa). Stages were I (n = 1), II (n = 1), III (n =
1) and IV (n = 1). Two cases had increased LDH levels and three reported B symptoms. IPI scores
were 0 (n = 1), 2 (n = 2) and 3 (n = 1). All cases exhibited plasmablastic morphology. By
immunohistochemistry, cases were positive for cytoplasmic ALK, MUM1, CD45, and EMA; they
marked negative for CD3, CD30 and CD20. Studies for EBV and HHV-8 were negative. The
survival for the patients with stage I, II, III and IV were 13, 62, 72 and 11 months, respectively.
Conclusion: ALK-DLBCL is a distinct variant of DLBCL with plasmacytic differentiation, which is
characterized by a bimodal age incidence curve, primarily nodal involvement, plasmablastic
morphology, lack of expression of CD20, aggressive behavior and poor response to standard
therapies, although some cases can have prolonged survival as the cases reported in this study.
ALK-DLBCL does not seem associated to immunosuppression or the presence of EBV or HHV8.
Further prospective studies are needed to optimize therapies for this entity.
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Background
DLBCL is the most common histological variant of NHL.
It encompasses multiple subtypes and has heterogeneous
clinical and pathological features. In 1997, Delsol and
colleagues reported seven cases of a distinct variant of
DLBCL expressing rearrangements of the ALK gene [1].
The plasmablastic appearance and CD20-negativity of
ALK-DLBCL makes this entity a potentially diagnostic
challenge with a broad differential diagnosis. Clinically,
ALK-DLBCL shows very aggressive behavior, high relapse
rate and lack of response to standard regimens.
Although in the initial report by Delsol and colleagues the
classic ALK gene rearrangement observed in ALCL could
not be shown [1], modern techniques have been able to
prove recurrent chromosomal abnormalities in ALK-
DLBCL. The most commonly observed cytogenetic abnor-
mality is t(2;17)(p23;q23) or clathrin/ALK [2-10]. The
classic ALCL-related t(2;5)(p23;q35) or nucleophosmin/
ALK has also been described [11-13]. Other rare cytoge-
netic abnormalities have been reported [14,15].
The main objective of this study was to describe the clin-
icopathological characteristics of four additional cases of
ALK-DLBCL and compare them with those of 46 litera-
ture-reported cases.
Materials and methods
Four cases of ALK-DLBCL were identified from the Hema-
tology and Medical Oncology consultation files at the
Edgardo Rebagliati Martins Hospital in Lima, Peru
between January 1, 1997 and June 30, 2008. Clinical and
laboratory information for each of the four patients was
obtained through physician interview and medical chart
review, after approval of this study by the IRB. Routine
hematoxylin and eosin-stained sections were prepared
from formalin-fixed and/or B5-fixed paraffin blocks.
Immunohistochemical analysis included a broad panel of
antibodies against ALK1 (Dako, Carpinteria, CA; dilution
1:50), CD45 (Dako; dilution 1:400), CD4 (Novocastra,
Newcastle upon Tyne, UK; dilution 1:20), CD56 (Sanbio,
Uden, The Netherlands; 1:200), CD20 (Dako; dilution
1:100), CD79a (Dako; dilution 1:25) and light chains of
immunoglobulin. The samples were also stained for
CD30 (Novocastra; dilution 1:100) and EMA (Dako; dilu-
tion 1:50), which are usually expressed by ALCL cells.
Immunohistochemical studies for Epstein Barr virus
(EBV) and human herpesvirus 8 (HHV-8) were performed
at the Department of Pathology of the Rhode Island Hos-
pital in Providence, RI. EBV clone was CS1-4 (Dako; dilu-
tion 1:500) obtained through heat retrieval pretreatment
with Target Retrieval solution (Dako) for 25 minutes.
HHV8 clone was 13B10 (Vector Laboratories, Burlin-
game, CA; dilution 1:50) obtained through heat retrieval
pretreatment with Target Retrieval solution (Dako) for 25
minutes. Cytogenetic studies by FISH looking for ALK
gene rearrangement were performed at the Department of
Cytogenetics of the Tufts Medical Center in Boston, MA.
The immunohistochemical analysis for HHV-8 and
cytogenetic studies were performed in only two of the
present cases. Further studies could not be attempted on
the other two cases due to lack of available remaining
specimen.
For the review, we performed a literature search using
Pubmed/MEDLINE looking for articles reporting clinico-
pathological data in patients with ALK-DLBCL through
December 2008. Eighteen articles were considered for this
review. Data were gathered on age, sex, pattern of ALK
expression, ALK gene rearrangement variety, expression of
CD30, CD45, plasma cell, B-cell, T-cell and NK-cell mark-
ers, EMA and light chain, heavy chain gene and T-cell
receptor gene rearrangements, presence of EBV, site of pri-
mary disease, clinical stage, LDH levels, IPI score, therapy
at presentation and at relapse, outcome, survival in
months and cause of death. Survival analyses were
attempted using Kaplan-Meier estimates for age, sex, T-cell
marker expression, primary site of presentation, clinical




A summary of the clinical features of the four patients is
provided in Table 1.
Case 1
A 27-year-old male patient presented with multifocal
bone lesions detected with bone scintigraphy. Patient also
reported the presence of B symptoms. LDH levels were
elevated. Serum protein electrophoresis (SPEP) did not
show a monoclonal spike. A computed tomography (CT)
scan of the thorax and abdomen showed no mass lesions
or additional lymphadenopathy. An incisional biopsy of
bone was performed, which showed a diffuse lymphoma
of plasmablastic appearance. A staging bone marrow aspi-
ration and biopsy was positive for involvement by lym-
phoma. Patient was staged as IVB and underwent six
cycles of EPOCH (cyclophosphamide, vincristine, doxo-
rubicin, etoposide and prednisone) with persistent bone
marrow infiltration at the end of the initial therapy. He is
currently receiving hyperCVAD (hyperfractionated cyclo-
phosphamide, vincristine, doxorubicin and dexametha-
sone alternating with cytarabine and methotrexate). At 11
months, he was alive with persistent disease.
Case 2
A 41-year-old male patient presented with history of nasal
obstruction for one month. He was otherwise asympto-Journal of Hematology & Oncology 2009, 2:11 http://www.jhoonline.org/content/2/1/11
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matic with an excellent performance status and had no
significant past medical history. Hematologic, basic meta-
bolic, liver function studies and LDH levels were within
normal limits. SPEP did not show monoclonal spike. CT
scan of the head, neck, chest, abdomen and pelvis
revealed only a mass in the right nasal fossa. Biopsy of
tumor was performed revealing a tumor with plasmablas-
tic morphology. Staging bone marrow was negative. Due
to an initial diagnosis of solitary plasmacytoma, patient
received involved field radiation therapy. At 13 months,
he was alive and free of disease.
Case 3
A 13-year-old female patient presented with a rapidly
enlarging left neck mass and B symptoms. Physical exam-
ination and radiological studies showed axillary and
mediastinal lymph nodes and costal bone involvement. A
biopsy of the cervical mass was performed and revealed an
aggressive lymphoma with plasmablastic features. Bone
marrow biopsy was negative for lymphoma. SPEP was not
performed. She received the regimen LNH96-2002, which
is based on induction with vincristine, prednisone, cyclo-
phosphamide, daunorubicin, L-asparaginase and meth-
otrexate; followed by consolidation based on
cyclophosphamide, cytarabine, methotrexate then inten-
sification with vincristine and doxorubicin and mainte-
nance based on methotrexate and mercaptopurine. She
had a complete response to the induction phase and then
received consolidation and maintenance. She has 62
months alive and free from recurrence.
Case 4
A 70-year-old male patient presented with cervical, axil-
lary and inguinal lymphadenopathy without B symp-
toms. Bone marrow was not involved. He had a
performance status of 2. Cervical lymph node biopsy was
done showing a diffuse lymphoma with plasmablastic
appearance. LDH levels were within normal limits. SPEP
was not performed. Patient was considered stage IIIB. IPI
score was 3 out of 5. He received CHOP-21 regimen for six
cycles and achieved a complete response. He is alive with
72 months free from recurrence.
Pathological aspects of the reported cases
All four cases showed plasmablastic morphologic features
with effacement of the normal architecture by sheets of
tumor cells. The neoplastic cells in all cases were large
with round, regular, with centrally located nuclei, dis-
persed chromatin, single central, prominent nucleolus,
and moderate eosinophilic or amphophilic cytoplasm.
Table 2 provides a summary of the immunohistochemical
characteristics in the four reported cases. All tested cases
were positive for CD45, MUM1 (Figure 1), and EMA (Fig-
ure 2), and were negative for CD4, CD20 (Figure 3) and
CD30. All cases were positive for ALK in a granular cyto-
plasmic distribution (Figure 4), which has been described
Table 1: Clinical characteristics of the reported cases
Case Age Sex Primary site Bone marrow involvement Stage IPI Therapy Survival (Months) Outcome
1 27 M Bone Yes IVB 3 HyperCVAD 11 Alive, with disease
2 41 F Nasal fossa No IA 0 Radiotherapy 13 Alive, NED
3 13 F Cervical LN No IIB 2 LNH96-2002 62 Alive, NED
4 70 M Cervical LN No IIIB 3 CHOP 72 Alive, NED
IPI – International Prognostic Index.
NED – no evidence of disease.
LN – lymph node.
HyperCVAD – hyperfractionated cyclophosphamide, vincristine, doxorubicin and dexamethasone alternating with cytarabine and methotrexate.
CHOP – cyclophosphamide, doxorubicin, vincristine, prednisone.
Negative CD20 expression in ALK-DLBCL Figure 1
Negative CD20 expression in ALK-DLBCL.Journal of Hematology & Oncology 2009, 2:11 http://www.jhoonline.org/content/2/1/11
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in clathrin/ALK-associated cases. FISH by standard meth-
ods was unsuccessful as the examined pathological sam-
ples were decalcified causing excessive background
autofluorescence.
Discussion and review of the literature
Pathological aspects
Morphological features
ALK-DLBCL is an entity with immunoblastic or plasmab-
lastic microscopical appearance with round nuclei, prom-
inent single central nucleoli, and moderate amounts of
variably eosinophilic cytoplasm.
DLBCL with plasmablastic features and terminal B-cell
differentiation represents a heterogeneous spectrum of
distinct entities [16]. Differential diagnosis of ALK-DLBCL
should include lymphoblastic lymphoma, anaplastic var-
iants of DLBCL, plasmablastic lymphoma (PBL), primary
effusion lymphoma (PEL), solid variants of PEL and plas-
mablastic myeloma.
It is important to note that few cases of ALK-DLBCL were
treated initially as ALCL due to morphological appear-
ance, CD20-negativity and presence of ALK-positive stain-
ing [5,7]. ALK-positive ALCL, although a T-cell
lymphoma, should be considered in the differential diag-
nosis of ALK-DLBCL given its good prognosis [17].
Immunohistochemistry (see Table 3)
The most commonly observed ALK staining pattern was
cytoplasmic and granular, caused by clathrin-ALK fusion.
This pattern is explained by the function of clathrin,
which is present in coated vesicles necessary for at least
50% of the endocytic activity of the cell [18,19]. In con-
trast, the NPM-ALK fusion protein seen in ALCL has a
characteristic nuclear and cytoplasmic sub-cellular locali-
zation pattern, which was found in a few cases. The gene
NPM1, which codes for nucleophosmin, is frequently
overexpressed and rearranged in human cancer and has
proto-oncogenic and tumor suppressor features [20].
ALK-DLBCL presents 100% positivity for plasmacytic dif-
ferentiation markers like CD138, VS38c and MUM1; EMA
was expressed in 97% of the cases. B-cell related antigens
such as CD20 and CD79a were rarely expressed in ALK-
DLBCL (11% and 18%, respectively). These observations
support the inference that ALK-DLBCL is derived from
MUM1 expression in ALK-DLBCL Figure 2
MUM1 expression in ALK-DLBCL.
EMA expression in ALK-DLBCL Figure 3
EMA expression in ALK-DLBCL.
Granular cytoplasmic ALK expression in ALK-DLBCL Figure 4
Granular cytoplasmic ALK expression in ALK-
DLBCL.Journal of Hematology & Oncology 2009, 2:11 http://www.jhoonline.org/content/2/1/11
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Table 2: Morphology and immunohistochemical characteristics of the reported cases
Case Morphology ALK CD45 CD20 CD79a CD4 CD56 MUM1 CD30 EMA Lambda EBV HHV8
1 Plasmablastic + + - - - - + - ND + - ND
2 Plasmablastic + + - + - - + - + + - -
3 Plasmablastic + + - - - - + - + + - -
4 Plasmablastic + + - - - - + - + - - ND
ALK – anaplastic lymphoma kinase.
EMA – epithelial membrane antigen.
EBV – Epstein Barr virus.
HHV8 – human herpesvirus 8.
ND – not done.
Table 3: Immunohistochemical and molecular features of 50 cases of ALK-DLBCL reported in the literature
Number studied Number positive/weak %
Immunohistochemistry




VS38c/CD138/MUM1 39 39 100
EMA 38 37 97
CD45 27 19/2 78
CD4 40 11/5 40
CD57 24 3/5 33
Perforin 24 2 8
CD20 44 4/1 11
CD79a 44 6/2 18
CD30 45 5 11
EBV 17 0 0
HHV8 2 0 0
Molecular studies




IgH gene rearrangement 20 17 85
TCR gene rearrangement 4 1 25
EBER CISH 12 0 0
ALK – anaplastic lymphoma kinase
EMA – epithelial membrane antigen
EBV – Epstein Barr virus
HHV8 – human herpesvirus 8
IgH – immunoglobulin heavy chain
TCR – T-cell receptor
EBER – EBV-encoded RNA
CISH – chromogenic in situ hybridizationJournal of Hematology & Oncology 2009, 2:11 http://www.jhoonline.org/content/2/1/11
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post-germinal B-cell lymphocytes that have undergone
class switching and plasmacytic differentiation. Further-
more, expression of monotypic cytoplasmic light chain
occurred in 85% of all cases. Based on these findings, ALK-
DLBCL falls into the category of non-GC DLBCL. Patients
with DLBCL of non-GC molecular or immunhistochemi-
cal profile have worse clinical outcomes than their coun-
terparts of GC-like origin [21-23]. Higher intensity
regimens or agents used in therapy of plasma cell mye-
loma should undergo prospective studies in this popula-
tion, which is unlikely to have higher benefits from
current standard therapies (i.e. CHOP).
CD45 was expressed variably positive in 70% of cases, T-
cell markers like CD4 was found in 40% of cases and NK
markers like CD57 was positive in 33% of cases. T-cell
marker expression did not play a role in survival (p =
0.37). The reason for aberrant T-cell and/or NK-cell mark-
ers expression is unknown; however, unusual T-cell mark-
ers expression has been seen in other B-cell
lymphoproliferative conditions such as CLL, HCL and
MCL [24]. CD56 has also been found expressed in B-cell
lymphomas such as DLBCL and FL [25]. The clinical
impact of aberrant T-cell or NK-cell markers in B-cell lym-
phoproliferative disorders is unknown but deserves atten-
tion for potential diagnostic, prognostic and/or
therapeutic approaches.
The four cases reported in the present study were negative
for the presence of EBV using LMP-1. From the literature,
12 cases were negative using EBER chromogenic in situ
hybridization (CISH), which is more sensitive than LMP-
1. Hence, ALK-DLBCL does not seem to be associated to
EBV. In contrast, EBV has been associated with other
DLBCL with plasmacytic differentiation such as plasmab-
lastic lymphoma in HIV-infected patients [26]. The pres-
ence of HHV-8 was evaluated in two cases of our series
and was negative in both. HHV-8 is involved in the patho-
genesis of other entities with terminal B-cell differentia-
tion such as classic and solid variants of PEL [27]. No virus
has been associated to the development of ALK-DLBCL
thus far.
Molecular studies (see Table 3)
As mentioned above, the most frequent ALK gene rear-
rangement was clathrin-ALK in 75% of cases; however
17% corresponded to NPM-ALK fusion. ALK gene is
located on chromosome 2p23 and encodes a tyrosine
kinase receptor belonging to the insulin receptor super-
family, which is normally silent in lymphoid cells [28]
and it could be translocated to either the clathrin gene
locus located on chromosome 17q23 or to the NPM1
gene located on chromosome 5q35, constituting the
clathrin-ALK and NPM-ALK fusion products, respectively.
In few cases, the actual ALK gene rearrangement could not
be demonstrated or was not reported [29-32].
All ALK fusion proteins share two essential characteristics:
1) presence of an N-terminal partner protein, a gene pro-
moter which controls aberrant transcription of ALK chi-
meric mRNA and the expression of its encoded fusion
protein, and 2) presence of an oligomerization domain in
the sequence of the ALK fusion partner protein which
mediate constitutive self association of the ALK fusion
causing constant ALK domain activation. Oncogenesis
occurs from ensuing dimerization leading to constitutive
activation of ALK tyrosine kinase activity. Stachurski and
colleagues [15] described a novel mechanism of ALK acti-
vation by means a cryptic 3'ALK gene insertion into chro-
mosome 4q22-24. The role of this anomaly in
lymphomagenesis is unclear.
Table 4: Clinical features of 50 cases of ALK-DLBCL reported in 
the literature
N% / r a n g e
Age, years (n = 47) 38 9 – 72
Sex (n = 50)
Male 38 76
Female 12 24
Site of involvement (n = 46)





Liver and spleen 4 18
Head and neck 3 14
Gastrointestinal tract 3 14
Other* 8 36
Clinical stage (n = 47)
I – II 20 43
III – IV 27 57




Relapsed cases 18 44
Salvage HSCT 8 20
Survival time, months (n = 36) 24 3 – 156
HSCT – hematopoietic stem cell transplantation
*Includes bone marrow, CNS, gonads and muscleJournal of Hematology & Oncology 2009, 2:11 http://www.jhoonline.org/content/2/1/11
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Immunoglobulin heavy chain gene rearrangements were
detected by PCR analysis in 17 of 20 studied cases (85%).
The previous finding, along with the expression of mono-
typic cytoplasmic immunoglobulin light chain, confirms
the B-cell lineage of this disorder.
Clinical aspects (see Table 4)
Age and sex distribution
Forty-seven cases of ALK-DLBCL reported age of presenta-
tion. The average age of presentation was 38 years, ranging
from 9 to 72 years of age. Despite the small amount of
cases, we can already observe a bimodal age distribution.
Eleven cases of ALK-DLBCL have been reported in pediat-
ric population [2,5,7,8,12], accounting for 24% of the
total number of cases. In patients younger than 18 years,
the average age of presentation was 12.4 years and in
adults it was 43.4 years. There was no difference in sur-
vival between pediatric and adult cases (p = 0.97; Figure
5), despite more intensive therapies in pediatric popula-
tion.
In regards of sex distribution, the male to female ratio was
3:1; female cases accounted for 23% of the cases. In pedi-
atric cases, the male to female ratio was 1.8:1 and in adults
4.3:1. There was no statistical difference between the over-
all survival of men compared to women (p = 0.45).
Sites of involvement
Data on primary sites of presentation were available in 46
cases. Twenty-four cases (52%) were exclusively nodal in
origin. The most commonly affected areas were cervical
and mediastinal. Few cases presented with generalized
lymphadenopathy. The remaining cases (48%) had some
extranodal component and from these, only 6 were exclu-
sively extranodal. Most common extranodal sites of dis-
ease were bone, liver, spleen, gastrointestinal tract and the
head and neck region.
ALK-DLBCL differs somewhat from other subtypes of
DLBCL with plasmacytic differentiation. Plasmablastic
lymphoma (PBL), a CD20-negative DLBCL associated to
HIV and EBV coinfection, tends to present with extranodal
involvement, usually in oral and gastrointestinal sites;
nodal presentation in PBL has been reported in only 6%
of the cases [26]. In a similar fashion, PEL, another CD20-
negative DLBCL seen exclusively in association with HHV-
8, tends to present in body cavities such as pleura and per-
itoneum [27]. Although nodal PEL has been described
[33], available data on extracavitary or solid variants of
PEL is very limited. In the survival analysis, there was no
statistical difference between nodal and extranodal sites of
involvement (p = 0.58).
Clinical stage and IPI score
From 47 ALK-DLBCL cases of the literature, advanced
stage (i.e. III and IV) was reported in 57% of the cases; the
remainder 43% presented with stages I or II. As observed
in other malignant lymphoproliferative disorders, clinical
stage had a strong correlation with survival (p = 0.0055;
Figure 6).
The IPI score has been accepted as the standard method
for risk stratification in patients with DLBCL [34]. Unfor-
tunately, only 8 of the 50 reported cases (17%) had avail-
able data on IPI scores, including the 4 cases reported in
this study. Furthermore, the gathered data did not allow
the authors to calculate IPI scores as serum LDH levels and
performance status were seldom reported. Survival analy-
ses using IPI scores or LDH levels were not performed.
Kaplan-Meier survival estimates according to age in 50 ALK- DLBCL cases from the literature Figure 5
Kaplan-Meier survival estimates according to age in 
50 ALK-DLBCL cases from the literature.
Kaplan-Meier survival estimates according to clinical stage in  50 ALK-DLBCL cases from the literature Figure 6
Kaplan-Meier survival estimates according to clinical 
stage in 50 ALK-DLBCL cases from the literature.Journal of Hematology & Oncology 2009, 2:11 http://www.jhoonline.org/content/2/1/11
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Therapy and relapses
Data on therapy was available in 41 ALK-DLBCL cases. Of
these 32 cases (83%) received combination chemother-
apy, 6 cases (15%) received chemoradiotherapy and one
case (2%) received radiotherapy. Only one case [6]
received immunotherapy with rituximab despite the
CD20-negative nature of ALK-DLBCL; this patient died of
lymphoma 6 months after diagnosis. From the 34 cases
treated with chemotherapy, 12 cases (38%) were treated
with CHOP and the remaining 20 cases (62%) were
treated with more intensive regimens. From the 12 cases
treated with CHOP, 6 cases (50%) needed more therapy
due to relapsing disease and 4 cases (33%) died of pro-
gressive lymphoma.
In the 11 ALK-DLBCL pediatric cases, all regimens used
were highly intensive (i.e. BFM90 [35], LMB89 [36],
LMB96 [37], POG8719 [38]). Most of these regimens are
used successfully to treat children with lymphoblastic,
Burkitt and aggressive B-cell lymphomas. Of note, some
of the patients were enrolled in randomized clinical trials
that are still undergoing recruitment (i.e. ALCL99 [39]). In
contrast with the reported efficacy of these regimens in
other types of aggressive NHL, the success in ALK-DLBCL
was rather moderate with 6 patients (55%) alive at the
time of report.
In total, 18 ALK-DLBCL cases (44%) experienced refrac-
tory or relapsing disease. Most salvage regimens were
based on platinum-containing compounds (i.e. ESHAP,
DHAP, ICE). Hematopoietic stem cell transplantation
(HSCT) was performed in 8 of the refractory or relapsing
cases (44%) [1,5,7,10,11,14,30]. Four patients received
autologous HSCT, one patient underwent allogeneic
HSCT and 3 patients were treated with non-specified
HSCT. All but one of the cases died after transplantation;
the range of survival in transplanted cases was between 3
and 44 months after diagnosis. The case treated with allo-
geneic HSCT died of thrombotic thrombocytopenic pur-
pura (TTP) 7 months after transplantation [30].
From the 50 cases of the literature, the authors could
observe that standard CHOP regimen seems inadequate
to treat ALK-DLBCL given evidence of progressive disease
and multiple recurrences. The lack of expression of CD20
antigen in most cases of ALK-DLBCL makes the therapeu-
tic role of rituximab rather unclear. Nonetheless, rituxi-
mab should be used in the few CD20-expressing ALK-
DLBCL cases [32].
Outcome and survival
ALK-DLBCL was fatal in 56% of the cases. The most com-
mon cause of death was progressive lymphoma, observed
in 90% of the reported cases. Other causes of death
included TTP and infectious complications. The average
survival for the 36 cases in which survival times were
reported was 24 months. Multiple clinical factors such as
age, sex and nodal primary sites do not seem to correlate
with survival in ALK-DLBCL. The strongest factor associ-
ated to survival in ALK-DLBCL cases from the literature
was clinical stage at presentation; patients with advanced
stages had a median survival of 18 months while patients
with earlier stages have not reached their median survival
(Figure 6).
Conclusion
ALK-DLBCL is a distinct subtype of DLBCL with plasma-
cytic differentiation that affects pediatric and adult
patients. It has characteristic genetic abnormalities and
corresponding specific ALK-staining patterns with a prog-
nosis that depends largely on clinical stage. The clinical
course of ALK-DLBCL is aggressive with primary refractory
disease and high relapse rates. The classical CHOP regi-
men appears insufficient to treat this condition and
newer, more intensive therapies are needed. Given its
CD20-negativity, the role of rituximab in the treatment of
ALK-DLBCL is unclear. It would be of interest to try agents
borrowed from plasma cell myeloma regimens or agents
active in novel pathways in combination with chemother-
apy given ALK-DLBCL plasmacytic nature. Despite this
aggressiveness, some cases, even in advanced stages, could
have prolonged survival times as the authors describe in
the present article. Further basic and clinical research is
necessary to improve our understanding of the biology of
the different subtypes of DLBCL with plasmacytic differ-
entiation in order to identify patients with a better prog-
nosis and to develop newer therapeutic techniques.
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